July 1, 2021 A class action alleges Takeda and Par violated antitrust law when the two struck an agreement to keep the latter’s generic version of Amitiza off the market for up to six years.
June 21, 2018 A proposed class action claims 14 pharmaceutical companies' and wholesale distributors' allegedly deceptive marketing of opioids has led to what public health officials are calling 'the worse drug crisis in American history.'
November 16, 2017 Endo International PLC and three of its executives are facing a securities lawsuit claiming the parties failed to disclose to stockholders that the projected success of subsidiary Par Pharmaceutical Holdings, Inc. was due to allegedly illegal activity.
September 7, 2017 Endo International PLC and its board of directors are facing a proposed class action lawsuit alleging they misinformed the investing public about their reformulated opioid product that was purportedly resistant to abuse.
June 6, 2017 Seven more lawsuits have been filed this week as part of a multidistrict litigation that accuses the pharmaceutical companies of conspiring to fix generic drug prices.
